Monitoring and reversal of direct oral anticoagulants

Hematology (United States)

Volumn 2015, Issue 1, 2015, Pages 117-124

  Cuker, Adam ^a,b   Siegal, Deborah ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANDEXANET ALFA; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CIRAPARANTAG; DABIGATRAN; DIRECT ORAL ANTICOAGULANT; ECARIN; EDOXABAN; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; ARGININE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PROTHROMBIN; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); THROMBIN TIME; THROMBOSIS; ANALOGS AND DERIVATIVES; BLOOD CLOTTING TEST; CHEMISTRY; HEMOSTASIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ARGININE; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; DABIGATRAN; FACTOR VIIA; FACTOR XA; FACTOR XA INHIBITORS; HEMORRHAGE; HEMOSTASIS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PIPERAZINES; PROTHROMBIN; PYRAZOLES; PYRIDINES; PYRIDONES; RECOMBINANT PROTEINS; RIVAROXABAN; THIAZOLES; THROMBIN TIME;

EID: 85010931992     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2015.1.117     Document Type: Article

References (40)

1. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15): 2450-2458.
2. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100(9):1419-1426.
3. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1-16.
4. Kowalsk K, Nielsen J, Roy A, et al. Apixaban exposure and anti-Xa activity in nonvalvular atrial fibrillation patients: an application of population PK/PD analysis [abstract]. J Pharmacokinet Pharmacodyn. 2014;41(Suppl 1):S19: Abstract M-027.
5. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641.
6. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis J, Schulman S, Eikelboom JW. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015;13(3):353-359.
7. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4): 321-328.
8. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128-1139.
9. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015;39(3):288-294.
10. Favaloro EJ, Bonar R, Butler J, et al. Laboratory testing for new oral anticoagulants: a review of current practice. Pathology. 2013;45(4):435-437.
11. Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013;69(11):1875-1881.
12. Helin TA, Pakkanen A, Lassila R, et al. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem. 2013;59(5):807-814.
13. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11(8):1493-1502.
14. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015;49(7):777-783.
15. College of American Pathologists. Surveys 2013 Participant Summary for CGE, CGL, GCS, and ACM. Northfield, IL: College of American Pathologists; 2013.
16. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex vivo flow chamber. Thromb Haemost. 2007;98(4):883-888.
17. Tripodi A, Chantarangkul V, Guinet C, et al. The international normalized ratio calibrated for rivaroxaban has the potential to normalize Prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011;9(1):226-228.
18. Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res. 2015;135(6):1186-1190.
19. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost. 2013;19(5):522-528.
20. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579.
21. Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12(9):1428-1436.
22. Zahir H, Brown KS, Vandell A, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2014;131(1):82-90.
23. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39(3):395-402.
24. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost. 2011; 106(3):429-438.
25. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217-224.
26. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8(2):83-90.
27. Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014;111(5):989-995.
28. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141-2142.
29. Hollenbach S, Lu G, DeGuzman F, et al. Andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model: only andexanet reverses markers of FXa-mediated anticoagulation [abstract]. Circulation. 2014;130(Suppl 2):A14657: Abstract 14657.
30. van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J. In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran [abstract]. Blood. 2012;120(21): Abstract 3418.
31. Grottke O, Honickel M, van Ryn J, ten Cate H, Spronk H, Rossaint R. Bloods loss in dabigatran anticoagulated pigs with polytrauma is significantly reduced by early therapy with activated and non-activated prothrombin complex concentrates [abstract]. Circulation. 2014; 130(Suppl 2): Abstract 18544.
32. Toth J, Gan G, van Ryn J, et al. Reversal of dabigatran's anticoagulant activity in the monkey by a specific antidote and pharmacokinetic and pharmacodynamic modeling [abstract]. Blood. 2012;120(21): Abstract 22.
33. Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers [abstract]. Circulation. 2013;128(22 Supplement): Abstract 17765.
34. Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects [abstract]. Blood. 2014;124(21):344.
35. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-520.
36. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451.
37. Crowther M, Levy GG, Lu G, et al. A phase 2 randomized, doubleblind, placebo-controlled trial demonstrating reversal of edoxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (FXa) inhibitors [abstract]. Blood. 2014;124(21):4269.
38. Crowther M, Kitt M, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors [abstract]. J Thromb Haemost. 2013;11(Suppl 2):30.
39. Crowther M, Levy GG, Lu G, et al. ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial demonstrating reversal of apixabaninduced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors [abstract]. Circulation. 2014;130(23):2105.
40. Herzog E, Kaspereit F, Krege W, et al. Effective reversal of edoxabanassociated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology. 2015;122(2):387-398.